List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4703192/publications.pdf Version: 2024-02-01

	57752	30081
38,445	44	103
citations	h-index	g-index
111	111	53646
docs citations	times ranked	citing authors
	38,445 citations 111 docs citations	38,445 44 citations h-index 111 111 docs citations 1111 times ranked

#	Article	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	13.7	8,569
2	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	13.7	4,989
3	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	13.7	3,269
4	Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	13.7	2,858
5	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	10.2	2,625
6	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	13.7	2,123
7	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Clobal Burden of Disease Study 2016. Lancet, The, 2018, 392, 1015-1035.	13.7	2,005
8	Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 439-458.	10.2	2,005
9	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 56-87.	10.2	1,064
10	Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016. New England Journal of Medicine, 2018, 379, 2429-2437.	27.0	959
11	The prevalence of vertebral deformity in European men and women: The european vertebral osteoporosis study. Journal of Bone and Mineral Research, 1996, 11, 1010-1018.	2.8	783
12	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	13.7	716
13	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	13.7	638
14	Incidence of Vertebral Fracture in Europe: Results From the European Prospective Osteoporosis Study (EPOS). Journal of Bone and Mineral Research, 2002, 17, 716-724.	2.8	551
15	The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019, 4, 934-947.	8.1	372
16	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	13.7	335
17	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	13.7	294
18	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019. 4, 913-933.	8.1	259

#	Article	IF	CITATIONS
19	Number and Type of Vertebral Deformities: Epidemiological Characteristics and Relation to Back Pain and Height Loss. Osteoporosis International, 1999, 9, 206-213.	3.1	257
20	Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International, 2003, 14, 19-26.	3.1	251
21	The Association between Common Vitamin D Receptor Gene Variations and Osteoporosis: A Participant-Level Meta-Analysis. Annals of Internal Medicine, 2006, 145, 255.	3.9	219
22	Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). Bone, 2003, 33, 505-513.	2.9	192
23	Incidence of Limb Fracture across Europe: Results from the European Prospective Osteoporosis Study (EPOS). Osteoporosis International, 2002, 13, 565-571.	3.1	191
24	The global burden of falls: global, regional and national estimates of morbidity and mortality from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i3-i11.	2.4	185
25	Validity of Self-Report of Fractures: Results from a Prospective Study in Men and Women Across Europe. Osteoporosis International, 2000, 11, 248-254.	3.1	177
26	Prevalent Vertebral Deformity Predicts Incident Hip though not distal Forearm Fracture: Results from the European Prospective Osteoporosis Study. Osteoporosis International, 2001, 12, 85-90.	3.1	159
27	Duloxetine Versus Placebo in Patients With Chronic Low Back Pain: A 12-Week, Fixed-Dose, Randomized, Double-Blind Trial. Journal of Pain, 2010, 11, 1282-1290.	1.4	150
28	Health Impact Associated with Vertebral Deformities: Results from the European Vertebral Osteoporosis Study (EVOS). Osteoporosis International, 1998, 8, 364-372.	3.1	125
29	Improving Risk Assessment: Hip Geometry, Bone Mineral Distribution and Bone Strength in Hip Fracture Cases and Controls. The EPOS Study. Osteoporosis International, 2002, 13, 48-54.	3.1	122
30	Influence of Physical Activity on Vertebral Deformity in Men and Women: Results from the European Vertebral Osteoporosis Study. Journal of Bone and Mineral Research, 1997, 12, 813-819.	2.8	103
31	A 2-year Follow-up Study on Bone Mineral Density and Markers of Bone Turnover in Patients with Long-standing Insulin-Dependent Diabetes Mellitus. Osteoporosis International, 1998, 8, 399-403.	3.1	95
32	Hip geometry, bone mineral distribution, and bone strength in European men and women: the EPOS study. Bone, 2000, 27, 151-159.	2.9	94
33	The Relationship Between Bone Density and Incident Vertebral Fracture in Men and Women. Journal of Bone and Mineral Research, 2002, 17, 2214-2221.	2.8	94
34	Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: The GENOMOS study. Bone, 2008, 42, 969-981.	2.9	91
35	Low BMD is less predictive than reported falls for future limb fractures in women across Europe: results from the European Prospective Osteoporosis Study. Bone, 2005, 36, 387-398.	2.9	88
36	Survey response rates: national and regional differences in a European multicentre study of vertebral osteoporosis Journal of Epidemiology and Community Health, 1995, 49, 87-93.	3.7	79

#	Article	IF	CITATIONS
37	Anthropometric Measurements and Vertebral Deformities. American Journal of Epidemiology, 1997, 146, 287-293.	3.4	65
38	The influence of family history of hip fracture on the risk of verterbral deformity in men and women: The European vertebral osteoporosis study. Bone, 1997, 20, 145-149.	2.9	65
39	The influence of alcohol consumption on the risk of vertebral deformity. Osteoporosis International, 1997, 7, 65-71.	3.1	65
40	Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. Osteoporosis International, 1997, 7, 72-78.	3.1	62
41	Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. European Journal of Endocrinology, 2009, 160, 899-907.	3.7	57
42	The prevalence of 6 weeks postpartum abnormal glucose tolerance in Caucasian women with gestational diabetes. Diabetes Research and Clinical Practice, 2009, 84, 239-244.	2.8	57
43	Falls explain between-center differences in the incidence of limb fracture across Europe. Bone, 2002, 31, 712-717.	2.9	47
44	Height and body mass index in oslo, norway, compared to other regions of europe: do they explain differences in the incidence of hip fracture?. Bone, 1995, 17, 347-350.	2.9	46
45	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. Injury Prevention, 2020, 26, i12-i26.	2.4	44
46	Defining Incident Vertebral Deformities in Population Studies: A Comparison of Morphometric Criteria. Osteoporosis International, 2002, 13, 809-815.	3.1	42
47	Does location of vertebral deformity within the spine influence back pain and disability?. Annals of the Rheumatic Diseases, 2000, 59, 368-371.	0.9	41
48	Bone mineral density and hip structural analysis in type 1 diabetic men. European Journal of Endocrinology, 2007, 156, 123-127.	3.7	41
49	Visceral fat reference values derived from healthy European men and women aged 20-30 years using GE Healthcare dual-energy x-ray absorptiometry. PLoS ONE, 2017, 12, e0180614.	2.5	39
50	The associations between cardiometabolic risk factors and visceral fat measured by a new dual-energy X-ray absorptiometry-derived method in lean healthy Caucasian women. Endocrine, 2014, 47, 500-505.	2.3	37
51	Whom to treat? The contribution of vertebral X-rays to risk-based algorithms for fracture prediction. Results from the European Prospective Osteoporosis Study. Osteoporosis International, 2006, 17, 1369-1381.	3.1	34
52	Determinants of the Size of Incident Vertebral Deformities in European Men and Women in the Sixth to Ninth Decades of Age: The European Prospective Osteoporosis Study (EPOS). Journal of Bone and Mineral Research, 2003, 18, 1664-1673.	2.8	33
53	Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017. PLoS ONE, 2020, 15, e0226766.	2.5	33
54	Are short women at risk for gestational diabetes mellitus?. European Journal of Endocrinology, 2010, 162, 491-497.	3.7	30

#	Article	IF	CITATIONS
55	Pregravid body mass index as a predictor of gestational diabetes mellitus. Diabetic Medicine, 2009, 26, 334-338.	2.3	29
56	Birth weight predicts the risk of gestational diabetes mellitus and pregravid obesity. Nutrition, 2014, 30, 39-43.	2.4	28
57	Osteoporosis in primary biliary cirrhosis of the liver. Przeglad Gastroenterologiczny, 2014, 2, 82-87.	0.7	27
58	Childhood Fractures Do Not Predict Future Fractures: Results From the European Prospective Osteoporosis Study. Journal of Bone and Mineral Research, 2009, 24, 1314-1318.	2.8	25
59	Bone Mineral Density and Markers of Bone Turnover in Boys with Constitutional Delay of Growth and Puberty. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2828-2830.	3.6	22
60	Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?. Diabetology and Metabolic Syndrome, 2015, 7, 94.	2.7	19
61	Vertebral Scheuermann's disease in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. Osteoporosis International, 2015, 26, 2509-2519.	3.1	19
62	National and regional trends in the prevalence of polycystic ovary syndrome since 1990 within Europe: the modeled estimates from the Global Burden of Disease Study 2016. Archives of Medical Science, 2021, 17, 343-351.	0.9	19
63	Factors influencing risk of macrosomia in women with gestational diabetes mellitus undergoing intensive diabetic care. Diabetes Research and Clinical Practice, 2008, 80, 405-410.	2.8	18
64	Adiponectin, visfatin and regional fat depots in normal weight obese premenopausal women. European Journal of Clinical Investigation, 2013, 43, 783-790.	3.4	18
65	Patient-Reported Outcomes in Women with Gestational Diabetes: a Longitudinal Study. International Journal of Behavioral Medicine, 2015, 22, 206-213.	1.7	18
66	Low predictive value of traditional risk factors in identifying women at risk for gestational diabetes. Acta Obstetricia Et Gynecologica Scandinavica, 2007, 86, 1165-1170.	2.8	17
67	The associations between G972R polymorphism of the IRS-1 gene, insulin resistance, salt sensitivity and non-dipper hypertension. Hypertension Research, 2011, 34, 1082-1086.	2.7	17
68	Intergenerational transmission of macrosomia in women with gestational diabetes and normal glucose tolerance. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 195, 113-116.	1.1	17
69	The Impact of Health Locus of Control and Anxiety on Self-Monitored Blood Glucose Concentration in Women with Gestational Diabetes Mellitus. Journal of Women's Health, 2018, 27, 209-215.	3.3	17
70	Serum Acylated Ghrelin, Adiponectin and Leptin Levels in Normal-weight and Obese Premenopausal Women. Hormone and Metabolic Research, 2007, 39, 835-839.	1.5	16
71	Serum adiponectin, bone mineral density and bone turnover markers in postâ€menopausal women with newly diagnosed Type 2 diabetes: a 12â€month followâ€up. Diabetic Medicine, 2012, 29, 62-69. 	2.3	16
72	Bone Health in Aging Men: Does Zinc and Cuprum Level Matter?. Biomolecules, 2021, 11, 237.	4.0	13

#	Article	IF	CITATIONS
73	The Impact of Fragility Fractures on Health-Related Quality of Life in Patients With Primary Sclerosing Cholangitis. Hepatitis Monthly, 2015, 15, e25539.	0.2	13
74	Epidemiology of hypertensive heart disease in Poland: findings from the Global Burden of Disease Study 2016. Archives of Medical Science, 2021, 17, 874-880.	0.9	12
75	Not insulin but insulin sensivity, leptin, and Cortisol are major factors regulating serum acylated ghrelin level in healthy women. Journal of Endocrinological Investigation, 2007, 30, 659-665.	3.3	11
76	Maternal Endothelin-1 and Cyclic Guanosine Monophosphate Concentrations in Pregnancies Complicated by Pregravid and Gestational Diabetes Mellitus. Gynecologic and Obstetric Investigation, 2010, 69, 46-50.	1.6	11
77	Degenerative inter-vertebral disc disease osteochondrosis intervertebralis in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. Rheumatology, 2017, 56, 1189-1199.	1.9	11
78	Evaluation of the prevalence of metabolic obesity and normal weight among the Polish population. Endokrynologia Polska, 2012, 63, 447-55.	1.0	11
79	Secondary Osteoporosis: Endocrine and Metabolic Causes of Bone Mass Deterioration. Journal of Osteoporosis, 2012, 2012, 1-2.	0.5	10
80	Changes in adiponectin level and fat distribution in patients with type 2 diabetes. European Journal of Clinical Investigation, 2014, 44, 192-199.	3.4	10
81	The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. Archives of Public Health, 2022, 80, 142.	2.4	9
82	Is the predictive power of previous fractures for new spine and non-spine fractures associated with biochemical evidence of altered bone remodelling? The EPOS study. Clinica Chimica Acta, 2002, 322, 121-132.	1.1	8
83	The association between past Chlamydia pneumoniae infection and markers of chronic inflammation in obese women. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 415-421.	2.9	7
84	Visceral fat, cardiometabolic risk factors, and nocturnal blood pressure fall in young adults with primary hypertension. Journal of Clinical Hypertension, 2019, 21, 1406-1414.	2.0	7
85	Selected adipokines and metabolic profiles in normal-weight women with abdominal obesity. Polish Archives of Internal Medicine, 2012, 122, 406-412.	0.4	7
86	Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study. Journal of Endocrinological Investigation, 2021, 44, 1243-1252.	3.3	4
87	Validation of a new index of body adiposity (BAI) to assess body fat in normal weight premenopausal Caucasian women. E-SPEN Journal, 2012, 7, e115-e118.	0.5	3
88	Hypothalamic–pituitary–adrenal axis activity, personality traits, and BCL1 and N363S polymorphisms of the glucocorticoid receptor gene in metabolically obese normal-weight women. Endocrine, 2014, 47, 315-321.	2.3	3
89	The impact of osteoporosis on health-related quality of life in patients after liver transplantation – a pilot study. Przeglad Gastroenterologiczny, 2015, 4, 215-221.	0.7	3
90	Changes in disease burden in Poland, 1990-2017: a systematic analysis for the GBD Study 2017. European Journal of Public Health, 2019, 29, .	0.3	3

#	Article	IF	CITATIONS
91	Associations of circulating irisin with 24-h blood pressure, total and visceral fat, and metabolic parameters in young adult hypertensives. Archives of Endocrinology and Metabolism, 2021, 65, 137-143.	0.6	3
92	Hypertension and beyond — does circulating irisin matter?. Arterial Hypertension, 2016, 20, 16-20.	0.3	3
93	Plasma adiponectin in hypertensive patients with and without metabolic syndrome. Arterial Hypertension, 2018, 22, 29-36.	0.3	3
94	Research update for articles published in <scp>EJCI</scp> in 2014. European Journal of Clinical Investigation, 2016, 46, 880-894.	3.4	2
95	Complex interplay among fat, lean tissue, bone mineral density and bone turnover markers in older men. Aging, 2020, 12, 19539-19545.	3.1	2
96	The Impact of Major and Trace Elements in Serum and Bone on Dual-Energy X-Ray Absorptiometry-Derived Hip Strength. Calcified Tissue International, 2022, 110, 674-684.	3.1	2
97	Research update for articles published in <scp>EJCI</scp> in 2013. European Journal of Clinical Investigation, 2015, 45, 1005-1016.	3.4	1
98	Analysis of the Relationship between the Levels of Androgens and Biochemical Bone Markers in Men Aged 60–75 Years. International Journal of Environmental Research and Public Health, 2020, 17, 106.	2.6	1
99	The influence of varying dietary sodium content on circadian blood pressure profile in patients with salt-sensitive hypertension. Arterial Hypertension, 2016, 20, 211-215.	0.3	1
100	Associations of the –344T>C polymorphism of CYP11B2 gene with 24-hour blood pressure profiles in middle-aged women with essential hypertension. Arterial Hypertension, 2015, 19, 23-28.	0.3	1
101	Thyroid Peroxidase Antibodies in Non-Autoimmune Hyperthyroidism Treated with Radioactive Iodine. Experimental and Clinical Endocrinology and Diabetes, 2016, 124, 572-576.	1.2	0
102	Impaired aldosterone response to the saline infusion test in patients with resistant hypertension and obstructive sleep apnea. Arterial Hypertension, 2015, 19, 13-18.	0.3	0
103	The civilization-related phenotypes of abnormal fatty tissue distribution: visceral obesity and sarcopoenic obesity. Arterial Hypertension, 2015, 19, 1-8.	0.3	0
104	The influence of non-pharmacological management of obesity on a diurnal blood pressure profile. Arterial Hypertension, 2016, 20, 68-72.	0.3	0
105	Comparison of the concentration of leptin between obese women and obese men with essential hypertension. Arterial Hypertension, 2016, 20, 108-112.	0.3	0
106	Testosterone assocition with blood pressure profile and left ventricular mass in a young hypertensive population. Arterial Hypertension, 2016, 20, 200-205.	0.3	0
107	Deaths, disability-adjusted life years and years of life lost due to elevated systolic blood pressure in Poland: estimates for the Global Burden of Disease Study 2016. Arterial Hypertension, 2018, 22, 95-103.	0.3	0
108	Selected adipokines and metabolic profiles in normal-weight women with abdominal obesity. , 2012,		0

108 122, 406-12.